Journal for ImmunoTherapy of Cancer · 2020 · 90 citations · 39 references
Veterinary MedicineImmunologyPharmacotherapyImmunopathologyImmunotherapyInflammationAnti-inflammatory PharmacologyCytokine BiologyCytokine-mediated PathologyInflammation In Infectious DiseaseInflammatory Disease PathologyInflammatory SignalingC-reactive Protein TestingInterleukin-6 InhibitionInterleukin-6 InhibitorsReceptor Antagonist AntibodiesSars-cov-2 InfectionSevere Acute Respiratory SyndromeSystemic Inflammation MarkersTreatment Of Coronavirus Infections
BACKGROUND: The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing. STUDY DESCRIPTION: In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease. CONCLUSIONS: This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.
39
Dexamethasone in Hospitalized Patients with Covid-19.
Peter Horby, Wei Shen Lim, Jonathan Emberson et al. · DiRROS repository (University of Maribor) · 2020 · 8K citations · Full text
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Bin Cao, Yeming Wang, Danning Wen et al. · New England Journal of Medicine · 2020 · 5.5K citations · Full text